Trenton, April 2, 2026 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ – www.hinj.org), released the following statement regarding today’s announcement on Section 232 tariffs on pharmaceuticals, aluminum, copper, and steel:
“America’s and New Jersey’s life sciences are fundamental to our national security and economic growth, but even more importantly, to patients worldwide who are desperately awaiting the next breakthrough treatment or cure. Tariffs on the ingredients or raw materials that produce those life-saving medicines, medical devices or innovative technologies will harm America’s global leadership, New Jersey’s workforce and economy, and dash the hopes of patients everywhere.”
Buteas continued, “As the life sciences work to increase our domestic R&D and manufacturing capabilities, strengthening national security and American jobs while still researching and discovering cutting-edge medical advances, these tariffs become a barrier to those efforts. This is particularly true for the small and mid-sized innovative companies, many of which are here in New Jersey, whose R&D investments are so significant they can’t absorb rising costs or rapidly shift manufacturing strategies while still delivering for patients.”
Buteas concluded, “We remain committed to working with policymakers on solutions that lower barriers to innovation, accelerate the development of new treatments and cures, and reinforce the United States’ and New Jersey’s global leadership in biopharma and medical technology innovation.”